Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma [0.03%]
卡非佐米在复发性多发性骨髓瘤二线及二线以后治疗中的应用
Divaya Bhutani,Jeffrey A Zonder
Divaya Bhutani
The development of proteasome inhibitors has been a major advance in therapy of multiple myeloma, accounting, in part, for the significant increase in the survival of patients diagnosed with this disease. Bortezomib was the first proteasome...
Clinical potential of midostaurin in advanced systemic mastocytosis [0.03%]
Midostaurin在晚期系统性肥大细胞增多症的临床潜力
Marie Olivia Chandesris,Gandhi Damaj,Olivier Lortholary et al.
Marie Olivia Chandesris et al.
Advanced (Ad) systemic mastocytoses (SM) include aggressive SM (ASM) and mast cell leukemia (MCL) with or without an associated clonal hematological non-mast cell lineage disease (AHNMD). They are rare (80%). We herein present a review of t...
Heather R Ferguson Bennit,Amber Gonda,Laura J Oppegard et al.
Heather R Ferguson Bennit et al.
Exosomes are nanosized lipid vesicles secreted into blood and other body fluids and serve as vehicles for intercellular communication. Despite being an important component of the tumor microenvironment (TME), exosomal targeting and uptake i...
Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma [0.03%]
程序性死亡配体-1阻断在霍奇金淋巴瘤治疗中的应用
Melody B Oncale,Hossein Maymani,Loretta J Nastoupil
Melody B Oncale
Immunotherapy is a rapidly evolving therapeutic option in the treatment of lymphoma. Neoplastic cells evade immune recognition through the programmed death (PD)-1/PD-ligand immune checkpoint pathway. Several novel agents have been developed...
Waldenström macroglobulinemia: biology, genetics, and therapy [0.03%]
Waldenstrom巨球蛋白血症：生物学、遗传学和治疗手段
Jonas Paludo,Stephen M Ansell
Jonas Paludo
Waldenström macroglobulinemia (WM) is a distinct clinicopathologic entity characterized by the presence of a lymphoplasmacytic lymphoma, a non-Hodgkin lymphoma, and IgM monoclonal gammopathy. WM is an indolent, uncommon malignancy mostly a...
Managing treatment-related peripheral neuropathy in patients with multiple myeloma [0.03%]
防治多发性骨髓瘤患者的治疗相关性外周神经病变
Sara Grammatico,Laura Cesini,Maria Teresa Petrucci
Sara Grammatico
Peripheral neuropathy is one of the most important complications of multiple myeloma treatment. Neurological damage can be observed at the onset of the disease, due to the effect of monoclonal protein or radicular compression, but more ofte...
Assessment and monitoring of patients receiving chemotherapy for multiple myeloma: strategies to improve outcomes [0.03%]
评估和监测多发性骨髓瘤化疗患者：改善预后的策略
Beth Faiman,Jason Valent
Beth Faiman
Improved understanding as to the biology of multiple myeloma (MM) and the bone marrow microenvironment has led to the development of new drugs to treat MM. This explosion of new and highly effective drugs has led to dramatic advances in the...
Ruxolitinib: a targeted treatment option for patients with polycythemia vera [0.03%]
鲁索利替尼：治疗真性红细胞增多症患者的一种靶向治疗选择
Kris Vaddi,Srdan Verstovsek,Jean-Jacques Kiladjian
Kris Vaddi
Polycythemia vera (PV) is a chronic myeloproliferative neoplasm characterized by erythrocytosis and the presence of Janus kinase (JAK) 2V617F or similar mutations. This review summarizes the pathophysiology of PV, the challenges associated ...
Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies [0.03%]
复发/难治性霍奇金淋巴瘤发病机制及治疗的进展：靶向治疗和移植策略为重点
Theodoros Karantanos,Ioannis Politikos,Vassiliki A Boussiotis
Theodoros Karantanos
Hodgkin's lymphoma (HL) is highly curable with first-line therapy. However, a minority of patients present with refractory disease or experience relapse after completion of frontline treatment. These patients are treated with salvage chemot...
Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas [0.03%]
伊匹拉利西姆治疗惰性B细胞恶性肿瘤：慢性淋巴细胞性白血病和小淋巴细胞性或滤泡性淋巴瘤
Yazan F Madanat,Mitchell R Smith,Alexandru Almasan et al.
Yazan F Madanat et al.
Chronic lymphocytic leukemia, small lymphocytic lymphoma, and follicular lymphoma are indolent B-cell lymphoproliferative disorders that mainly affect an older population. Although the majority of patients in need of treatment derive signif...